08:00 , Nov 23, 2015 |  BC Week In Review  |  Clinical News

Bilastine regulatory update

Taiho submitted an NDA in Japan for bilastine to treat allergic rhinitis, urticaria and itching resulting from skin diseases, including eczema/dermatitis, prurigo and cutaneous pruritus. The histamine H1 receptor (HRH1) antagonist is approved in the...
07:00 , May 7, 2012 |  BC Week In Review  |  Company News

Faes, Menarini sales and marketing update

Faes granted Menarini's Invida Holdings Pte. Ltd. exclusive rights to commercialize bilastine in Asia-Pacific markets. The territories include Australia, China, Thailand, Philippines, Singapore, Malaysia, Taiwan, New Zealand, Laos, Brunei, Pakistan, Mongolia and Papau New Guinea....
07:00 , Jul 19, 2010 |  BC Week In Review  |  Company News

Faes, Pierre Fabre sales and marketing update

Pierre Fabre received non-exclusive rights to market Faes Farma's Bilastine in France and Belgium. Pierre Fabre will co-market the histamine H1 receptor antagonist with Menarini Group (Florence, Italy) in France and Belgium, which has rights...
08:00 , Jan 21, 2008 |  BC Week In Review  |  Company News

Inspire, Faes deal

Inspire ended a 2006 deal to develop and commercialize Faes' oral bilastine in the U.S. and Canada and to market the ocular form worldwide (see BioCentury, Nov. 6, 2006). The oral form of the histamine...
07:00 , Jun 25, 2007 |  BC Week In Review  |  Company News

Inspire, Faes deal

FAE and ISPH amended a 2006 deal that granted ISPH exclusive U.S. and Canadian rights to commercialize and develop oral bilastine to treat allergic rhinitis (see BioCentury, Nov. 6, 2006). FAE is now responsible for...
08:00 , Nov 6, 2006 |  BC Week In Review  |  Company News

Inspire, Faes deal

FAE granted ISPH an exclusive license in the U.S. and Canada to develop and commercialize oral bilastine to treat or prevent rhinitis, as well as an exclusive license to the ocular formulation in various markets...
08:00 , Nov 6, 2006 |  BioCentury  |  Strategy

A shelf full of antihistamines

With its newly licensed oral histamine H1 receptor antagonist, Inspire Pharmaceuticals Inc. thinks it can cover the delivery preferences of patients in the crowded allergy space. Inspire (ISPH, Durham, N.C.) last week obtained U.S. and...
08:00 , Nov 6, 2006 |  BioCentury  |  Strategy

Bases covered

Bases covered...
00:52 , Nov 2, 2006 |  BC Extra  |  Company News

Inspire licenses Faes' bilastine

Faes (IBEX:FAE) granted ISPH an exclusive license in the U.S. and Canada to develop and commercialize oral bilastine to treat or prevent rhinitis, as well as an exclusive license to the ocular formulation in various...